Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study

• Main Authors: Fang Wang (Author), Xiaofei Li (Author), Yanting Shi (Author), He Zhou (Author), Gang Yang (Author), Ruixia Li (Author), Tong Wu (Author), Jie Liang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Adalimumab (ADA) is an effective treatment for inflammatory bowel disease (IBD), both ulcerative colitis (UC) and Crohn's disease (CD). The equal effect between the original ADA and biosimilars from Europe and the United States has been shown. However, the biosimilar of ADA is differ...